FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003148399> ?p ?o ?g. }

• W2003148399 endingPage "152" @default.
• W2003148399 startingPage "152" @default.
• W2003148399 abstract "Letters18 July 2006Imatinib Mesylate in the Treatment of Refractory Idiopathic Pulmonary Arterial HypertensionKaren C. Patterson, MD, Ariel Weissmann, MD, MPH, Tahamtan Ahmadi, MD, PhD, and Harrison W. Farber, MDKaren C. Patterson, MDFrom Boston Medical Center, Boston, MA 02118.Search for more papers by this author, Ariel Weissmann, MD, MPHFrom Boston Medical Center, Boston, MA 02118.Search for more papers by this author, Tahamtan Ahmadi, MD, PhDFrom Boston Medical Center, Boston, MA 02118.Search for more papers by this author, and Harrison W. Farber, MDFrom Boston Medical Center, Boston, MA 02118.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-145-2-200607180-00020 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Idiopathic pulmonary arterial hypertension (PAH) is a pathologic process of inappropriate vasoconstriction, vascular remodeling with smooth muscle cell hypertrophy, and in situ thrombosis, which eventually leads to right-heart failure and death. Current treatments primarily attenuate vasoconstriction and do not substantially reduce morbidity and mortality rates.Objective: To describe a patient with severe, refractory idiopathic PAH that did not respond to conventional treatment but did show clinical and hemodynamic response to imatinib mesylate therapy, which may affect vascular remodeling.Case Report: A 52-year-old man with rapidly progressive idiopathic PAH was evaluated for progressive dyspnea on exertion. Echocardiography and right-heart catheterization ...References1. Tapson VF, Gomberg-Maitland M, McLaughlin VV, Benza RL, Widlitz AC, Krichman A, et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest. 2006;129:683-8. [PMID: 16537868] CrossrefMedlineGoogle Scholar2. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148-57. [PMID: 16291984] CrossrefMedlineGoogle Scholar3. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med. 2005;353:1412-3. [PMID: 16192491] CrossrefMedlineGoogle Scholar4. Humbert M, Monti G, Fartoukh M, Magnan A, Brenot F, Rain B, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J. 1998;11:554-9. [PMID: 9596101] MedlineGoogle Scholar5. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005;115:2811-21. [PMID: 16200212] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Karen C. Patterson, MD; Ariel Weissmann, MD, MPH; Tahamtan Ahmadi, MD, PhD; Harrison W. Farber, MDAffiliations: From Boston Medical Center, Boston, MA 02118.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byThe treatment strategy of connective tissue disease associated pulmonary arterial hypertension: Evolving into the futureIdentification of Signal Pathways and Hub Genes of Pulmonary Arterial Hypertension by Bioinformatic AnalysisComprehensive review on novel targets and emerging therapeutic modalities for pulmonary arterial HypertensionPositioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and single‐arm efficacyIntracerebral hemorrhage as a rare complication of imatinib in a Philadelphia chromosome positive acute lymphoblastic leukemia pediatric patientTherapeutic Potential of Regorafenib—A Multikinase Inhibitor in Pulmonary HypertensionNovel Experimental Therapies for Treatment of Pulmonary Arterial HypertensionPulmonary arterial hypertension specific therapy: The old and the newMuscle Toxicity of Drugs: When Drugs Turn Physiology into PathophysiologyKIT as a therapeutic target for non-oncological diseasesDasatinib-induced pulmonary arterial hypertensionIdentifying “super responders” in pulmonary arterial hypertensionPDGF induces SphK1 expression via Egr-1 to promote pulmonary artery smooth muscle cell proliferationNovel investigational therapies for treating pulmonary arterial hypertensionLong-term safety and efficacy of imatinib in pulmonary arterial hypertensionNovel Targets of Drug Treatment for Pulmonary HypertensionEmerging Therapies and Future Directions in Pulmonary Arterial HypertensionTreatment of Chronic Right Heart FailurePathogenesis of Pulmonary Arterial HypertensionEfficacy and Safety of Long-Term Imatinib Therapy for Pulmonary Arterial HypertensionDelivery of Imatinib-Incorporated Nanoparticles into Lungs Suppresses the Development of Monocrotaline-Induced Pulmonary Arterial HypertensionExisting Drugs and Agents Under Investigation for Pulmonary Arterial HypertensionImatinib in Pulmonary Arterial Hypertension: C‐Kit InhibitionTreatment for Pulmonary Arterial Hypertension–Associated Right Ventricular DysfunctionImatinib for the Treatment of Pulmonary Arterial Hypertension and Pulmonary Capillary HemangiomatosisTargeting the PDGF Signaling Pathway in the Treatment of Non-Malignant DiseasesPulmonary Hypertension Associated with Connective Tissue DiseaseThe challenge of managing pulmonary arterial hypertension in adults with congenital heart diseaseA Lymphocyte-Dependent Mode of Action for Imatinib Mesylate in Experimental Pulmonary HypertensionPharmacologic treatments for pulmonary hypertension: exploring pharmacogenomicsImatinib Mesylate as Add-on Therapy for Pulmonary Arterial HypertensionImpression, SunsetTherapeutic Inhibition of Tyrosine Kinases in Systemic Sclerosis: A Review of Published Experience on the First 108 Patients Treated with ImatinibPulmonary vascular pathologyTargeting of Platelet-Derived Growth Factor Signaling in Pulmonary Arterial HypertensionMonitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant RecipientsApplications thérapeutiques non oncologiques des thérapies moléculaires cibléesA Process‐Based Review of Mouse Models of Pulmonary HypertensionWHO Group 1 pulmonary arterial hypertension: Current and investigative therapiesThe Pharmacological Treatment of Pulmonary Arterial HypertensionImplication of PDGF signaling in cigarette smoke-induced pulmonary arterial hypertension in ratRole of Src Tyrosine Kinases in Experimental Pulmonary HypertensionTreatment of Pulmonary HypertensionImatinib mesylate for the treatment of pulmonary arterial hypertensionHypoxia-inducible factor-1 α/platelet derived growth factor axis in HIV-associated pulmonary vascular remodelingMulti tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?Treating pulmonary arterial hypertension: current treatments and future prospectsTyrosine Kinase Inhibitors Are Potent Acute Pulmonary Vasodilators in RatsTreatment of pulmonary arterial hypertension with targeted therapiesEffect of Cocaine on Human Immunodeficiency Virus–Mediated Pulmonary Endothelial and Smooth Muscle DysfunctionThe Management of Acute Pulmonary Arterial HypertensionNew perspectives for the treatment of pulmonary hypertensionPulmonary arterial hypertension associated with systemic sclerosisSerotonin transporter interacts with the PDGFβ receptor in PDGF-BB-induced signaling and mitogenesis in pulmonary artery smooth muscle cellsVascular remodeling in pulmonary arterial hypertension: Multiple cancer-like pathways and possible treatment modalitiesPulmonary Arterial Hypertension Related to Scleroderma and Collagen Vascular DiseasesPulmonary Veno-occlusive DiseaseLung involvement in systemic sclerosisTargeting non-malignant disorders with tyrosine kinase inhibitorsReversible or Irreversible Remodeling in Pulmonary Arterial HypertensionImatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established TherapyToxicity and Monitoring of Immunosuppressive Therapy Used in Systemic Autoimmune DiseasesThe impact of Fli1 deficiency on the pathogenesis of systemic sclerosisHypertension artérielle pulmonaire et hémopathies malignesUpdate on Pulmonary Hypertension 2009New therapies for pulmonary arterial hypertension: an update on current bench to bedside translationThe role of calcium channel blockers, steroids, anticoagulation, antiplatelet drugs, and endothelin receptor antagonistsRole of Epidermal Growth Factor Inhibition in Experimental Pulmonary HypertensionIdiopathic and Familial Pulmonary Arterial HypertensionPDGF Receptor and its Antagonists: Role in Treatment of PAHFuture treatments in systemic sclerosisImatinib Mesylate Has The Potential to Exert Its Efficacy by Down-Regulating The Plasma Concentration of Platelet-Derived Growth Factor in Patients With Pulmonary Arterial HypertensionEvaluation of imatinib mesylate in the treatment of pulmonary arterial hypertensionTherapy for pulmonary arterial hypertension associated with systemic sclerosisTherapie der pulmonalarteriellen HypertonieEffects of Imatinib Mesylate on Renin–Angiotensin System (RAS) Activity during the Clinical Course of Chronic Myeloid LeukaemiaRecent Advances in the Treatment of Systemic SclerosisInflammation, Growth Factors, and Pulmonary Vascular RemodelingFuture Perspectives for the Treatment of Pulmonary Arterial HypertensionReversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemiaThe science of endothelin-1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: current understanding and future studiesProliferative capacity of vein graft smooth muscle cells and fibroblasts in vitro correlates with graft stenosisSignificant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertensionTransforming growth factor β as a therapeutic target in systemic sclerosisPediatric Pulmonary Hypertension: A Pharmacotherapeutic ReviewTherapies for scleroderma-related pulmonary arterial hypertensionNovel approaches to the pharmacotherapy of pulmonary arterial hypertensionChronic Pulmonary HypertensionTherapeutic targets in pulmonary arterial hypertensionExperiencia en el tratamiento de la hipertensión arterial pulmonar con imatinibCombined Tyrosine and Serine/Threonine Kinase Inhibition by Sorafenib Prevents Progression of Experimental Pulmonary Hypertension and Myocardial RemodelingEndothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertensionReview: Therapeutic advances in pulmonary arterial hypertensionPlatelet-derived Growth Factor Expression and Function in Idiopathic Pulmonary Arterial HypertensionAn Experimental Animal Model of Postobstructive Pulmonary HypertensionEffects of external wrapping and increased blood flow on atrophy of the baboon iliac arteryGenomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertensionUpdate in Pulmonary Arterial Hypertension 2007Induction of vascular atrophy as a novel approach to treating restenosis. A reviewNew Developments in the Pathogenesis and Management of Neonatal Pulmonary HypertensionExperience With Imatinib to Treat Pulmonary Arterial HypertensionPhase 2 and 3 Clinical Trials in Pulmonary Arterial HypertensionBases cellulaires et moléculaires de l'hypertension artérielle pulmonaireTraitement médical de l'hypertension artérielle pulmonairePulmonary arterial hypertension: current therapeutic strategiesAtrial SeptostomyPlatelet-Derived Growth Factor Is Increased in Pulmonary Capillary HemangiomatosisTreatment of pulmonary fibrosis in systemic sclerosis: Light at the end of the tunnel?Emerging treatments for pulmonary arterial hypertensionConnective Tissue Disease Associated Pulmonary Hypertension 18 July 2006Volume 145, Issue 2Page: 152-153KeywordsDeath ratesGlobal healthMorbidityOxygenPulmonary arteriesPulmonary hypertensionSmooth muscle cellsThrombosisVasoconstrictionVasodilators ePublished: 18 July 2006 Issue Published: 18 July 2006 Copyright & PermissionsCopyright © 2006 by American College of Physicians. All Rights Reserved.PDF downloadLoading ..." @default.
• W2003148399 created "2016-06-24" @default.
• W2003148399 creator A5044203041 @default.
• W2003148399 creator A5053303920 @default.
• W2003148399 creator A5065261698 @default.
• W2003148399 creator A5077388722 @default.
• W2003148399 date "2006-07-18" @default.
• W2003148399 modified "2023-10-13" @default.
• W2003148399 title "Imatinib Mesylate in the Treatment of Refractory Idiopathic Pulmonary Arterial Hypertension" @default.
• W2003148399 cites W1983657617 @default.
• W2003148399 cites W1987031019 @default.
• W2003148399 cites W2020924652 @default.
• W2003148399 cites W2036199559 @default.
• W2003148399 cites W2065613113 @default.
• W2003148399 cites W2072860615 @default.
• W2003148399 cites W2112604150 @default.
• W2003148399 cites W2121376498 @default.
• W2003148399 cites W2147944062 @default.
• W2003148399 cites W2166028076 @default.
• W2003148399 doi "https://doi.org/10.7326/0003-4819-145-2-200607180-00020" @default.
• W2003148399 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16847299" @default.
• W2003148399 hasPublicationYear "2006" @default.
• W2003148399 type Work @default.
• W2003148399 sameAs 2003148399 @default.
• W2003148399 citedByCount "133" @default.
• W2003148399 countsByYear W20031483992012 @default.
• W2003148399 countsByYear W20031483992013 @default.
• W2003148399 countsByYear W20031483992014 @default.
• W2003148399 countsByYear W20031483992015 @default.
• W2003148399 countsByYear W20031483992016 @default.
• W2003148399 countsByYear W20031483992017 @default.
• W2003148399 countsByYear W20031483992018 @default.
• W2003148399 countsByYear W20031483992019 @default.
• W2003148399 countsByYear W20031483992020 @default.
• W2003148399 countsByYear W20031483992021 @default.
• W2003148399 countsByYear W20031483992022 @default.
• W2003148399 crossrefType "journal-article" @default.
• W2003148399 hasAuthorship W2003148399A5044203041 @default.
• W2003148399 hasAuthorship W2003148399A5053303920 @default.
• W2003148399 hasAuthorship W2003148399A5065261698 @default.
• W2003148399 hasAuthorship W2003148399A5077388722 @default.
• W2003148399 hasConcept C121332964 @default.
• W2003148399 hasConcept C126322002 @default.
• W2003148399 hasConcept C142424586 @default.
• W2003148399 hasConcept C164705383 @default.
• W2003148399 hasConcept C178790620 @default.
• W2003148399 hasConcept C185592680 @default.
• W2003148399 hasConcept C2777583451 @default.
• W2003148399 hasConcept C2778729363 @default.
• W2003148399 hasConcept C2780194963 @default.
• W2003148399 hasConcept C2780930700 @default.
• W2003148399 hasConcept C3019892230 @default.
• W2003148399 hasConcept C71924100 @default.
• W2003148399 hasConcept C87355193 @default.
• W2003148399 hasConceptScore W2003148399C121332964 @default.
• W2003148399 hasConceptScore W2003148399C126322002 @default.
• W2003148399 hasConceptScore W2003148399C142424586 @default.
• W2003148399 hasConceptScore W2003148399C164705383 @default.
• W2003148399 hasConceptScore W2003148399C178790620 @default.
• W2003148399 hasConceptScore W2003148399C185592680 @default.
• W2003148399 hasConceptScore W2003148399C2777583451 @default.
• W2003148399 hasConceptScore W2003148399C2778729363 @default.
• W2003148399 hasConceptScore W2003148399C2780194963 @default.
• W2003148399 hasConceptScore W2003148399C2780930700 @default.
• W2003148399 hasConceptScore W2003148399C3019892230 @default.
• W2003148399 hasConceptScore W2003148399C71924100 @default.
• W2003148399 hasConceptScore W2003148399C87355193 @default.
• W2003148399 hasIssue "2" @default.
• W2003148399 hasLocation W20031483991 @default.
• W2003148399 hasLocation W20031483992 @default.
• W2003148399 hasOpenAccess W2003148399 @default.
• W2003148399 hasPrimaryLocation W20031483991 @default.
• W2003148399 hasRelatedWork W1984254745 @default.
• W2003148399 hasRelatedWork W2002247001 @default.
• W2003148399 hasRelatedWork W2070391470 @default.
• W2003148399 hasRelatedWork W2123135404 @default.
• W2003148399 hasRelatedWork W2161653304 @default.
• W2003148399 hasRelatedWork W2342278538 @default.
• W2003148399 hasRelatedWork W2367462925 @default.
• W2003148399 hasRelatedWork W2369852642 @default.
• W2003148399 hasRelatedWork W3149385070 @default.
• W2003148399 hasRelatedWork W1603953938 @default.
• W2003148399 hasVolume "145" @default.
• W2003148399 isParatext "false" @default.
• W2003148399 isRetracted "false" @default.
• W2003148399 magId "2003148399" @default.
• W2003148399 workType "article" @default.